Host: Charles Turck, PharmD, BCPS, BCCCP

Guest: Steven Maron, MD, MSc

Given the recent identification of actionable biomarkers like PD-L1 and MSI-H,1-3 it’s important to test patients with gastroesophageal cancer for these biomarkers as they may provide insights into options for a patient’s treatment plan.4,5 To learn more about how we can detect biomarkers and other key considerations for biomarker screening in gastroesophageal cancer, Dr. Charles Turck speaks with Dr. Steven Maron, a gastrointestinal oncologist at Memorial Sloan Kettering Cancer Center in New York.

References:

1. The Cancer Genome Atlas Network. Nature. 2014;513:202-209.
2. Fontana E, et al. Ther Adv Med Oncol. 2016;8:113-125.
3. Yang B, et al. J Exp Clin Cancer Res. 2019;38:283.
4. American Cancer Society. https://www.fightcancer.org/sites/default/files/Improving%20Access%20to%20Biomarker%20Testing_FINAL.pdf. Accessed July 20, 2024.
5. Catenacci DVT, et al. Future Oncol. 2019;15:2073-2082.

©2024 Amgen Inc. All rights reserved. USA-OCF-82400 9/24